A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects.
HGP-30-KLH vaccine in alum at doses of 10, 25, 50, and 100 micrograms/kg administered intramuscularly at weeks 0, 4, and 10 appear well-tolerated clinically. Local pain at the injection site, appears to be the main clinical toxicity. Laboratory parameters are not affected by administration of the vaccine candidate except for perhaps mild urinalysis abnormalities at the highest dose. This vaccine candidate has no apparent immunotoxicity and does not appear to affect lymphocyte populations or T-cell functional studies. Low levels and transient antibodies develop in a minority of subjects early after immunization with the vaccine candidate. These responses were observed in the lowest dose range. Higher doses, and longer follow-up will be needed to confirm this observation. T-cell proliferative responses to KLH and KLH-HGP-30 are consistent and may not be dose dependent, but the proliferative responses are variable and more data need to be accumulated. Preliminary, there appears to be an HGP-30-induced CTL response of HGP-30-coated EBV-transformed autologous B cell lines. This study was approved under an IND for the California Department of Health Services' Food and Drug Branch. They have provided excellent support and regulatory guidelines for this project. Future work will extend and confirm these initial observations.
Kahn
J O
JO
AIDS Program, San Francisco General Hospital, CA.
Stites
D P
DP
Scillian
J
J
Murcar
N
N
Stryker
R
R
Volberding
P A
PA
Naylor
P H
PH
Goldstein
A L
AL
Sarin
P S
PS
Simmon
V F
VF
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity; D000328:Adult; D000595:Amino Acid Sequence; D000818:Animals; D004353:Drug Evaluation, Preclinical; D005260:Female; D015683:Gene Products, gag / Q000276:immunology* / Q000633:toxicity; D015483:HIV Antibodies / Q000096:biosynthesis; D015488:HIV Antigens / Q000276:immunology* / Q000633:toxicity; D006679:HIV Seropositivity / Q000276:immunology*; D006433:Hemocyanins / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010455:Peptides / Q000276:immunology* / Q000633:toxicity; D014611:Vaccination / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D015683:Gene Products, gag; C052407:HGP-30 peptide, Human immunodeficiency virus-1; D015483:HIV Antibodies; D015488:HIV Antigens; D010455:Peptides; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin